Manufacturing essential API for Africa
to fight the COVID-19 crises, and beyond.
is a replication-deficient simian adenoviral vector, clinical stage vaccine candidate.
is a DNA-based vaccine candidate using electro-gene-transfer (EGT).
is a vaccine candidate based on a gorilla-derived replication-defective adenoviral vector.
is a therapeutic and prophylactic human monoclonal antibody candidate.
is a cell therapy candidate for the treatment of severe pneumonia due to COVID-19.
formerly known as COVAX,
is a measles vector vaccine candidate.
is a RBD, virus like particles display COVID-19 vaccine candidate.
is a real world data platform for deployment in Phases III and IV of clinical development.
is a recombinant nanoparticle vaccine candidate using Matrix-M™ adjuvant.
is a novel testing device aimed at the rapid detection of SARS-CoV-2 in saliva.
are neutralizing mAb candidates
to treat COVID-19 in LMICs .
is an online training programme for professional staff working in retirement homes and hospitals.
is a digital diagnostic platform for the non-invasive detecion of COVID-19.
is an oral, self-administered vaccine candidate against COVID-19.
to block viral entry into cells suited for the treatment of COVID-19.
is aimed to the detection of total antibody (mainly IgG and IgA) in saliva,
Exosomes containing immunogenic viral peptides as a new vaccine against Sars-CoV-2.
delivers flexible capacity for manufacturing the highest quality COVID-19 mAbs at a reasonable cost.
is a expression platform to mass-produce recombinant antigens and antibodies for reasonable cost.
is a recombinant BCG vaccine for the prevention of COVID-19 via the induction of trained immunity.
